Doxofylline for Pediatric Asthma Steps 1–4. Pediatric Asthma: New Role for an Old Drug

5Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

The panoply of anti-asthma drugs for children between 6 and 18 years is not limited to those reported in the guidelines. In this review, we will re-assess the role of doxofylline, a xanthine characterized by a much higher handling than that of theophylline, as add-on treatment in pediatric asthma grade 1–4. Ten studies evaluated doxofylline in the treatment of asthma of patients non-responsive to the first-line inhaled corticosteroids. Of these, two included children and one was exclusively pediatric. According to their results, doxofylline exerts a powerful bronchodilator and anti-inflammatory activity, which can be exploited when the inhaled oral corticosteroids are not sufficient to get the desired effect of reducing symptoms. Unlike theophylline, doxofylline does not require blood testing. It can be administered together with or as an alternative to a series of other drugs considered in additional therapy.

Cite

CITATION STYLE

APA

Fierro, V., Piscitelli, A. L., Battaglia, E., & Fiocchi, A. (2022, June 22). Doxofylline for Pediatric Asthma Steps 1–4. Pediatric Asthma: New Role for an Old Drug. Frontiers in Pediatrics. Frontiers Media S.A. https://doi.org/10.3389/fped.2022.772704

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free